uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2017-24-2-40-45uzspbgmu-415Research ArticleОРИГИНАЛЬНЫЕ РАБОТЫORIGINAL PAPERSВАРИАНТЫ С-572G ГЕНА ИНТЕРЛЕЙКИНА-6 И С-1112Т ГЕНА ИНТЕРЛЕЙКИНА-13 И ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ДИФФУЗНОГО ТОКСИЧЕСКОГО ЗОБАVARIANTS OF С-572G OF IL6 AND С-1112T OF IL13 GENES POLYMORPHISMS AND FEATURES OF THE CLINICAL COURSE OF DIFFUSE TOXIC GOITERПейкришвилиН. Э.PeikrishviliN. E.

очный аспирант кафедры терапии факультетской с курсом эндокринологии, кардиологии и функциональной диагностики с клиникой, Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова»

ул. Льва Толстого, д. 6/8, Санкт-Петербург, Россия, 197022

6-8 L’va Tolstogo street, Saint-Petersburg, Russia, 197022

nato47@ya.ruДораС. В.DoraS. V.doras2001@mail.ruВолковаА. Р.VolkovaA. R.volkovaa@mail.ruПантелееваА. А.PanteleevaA. A.aleksandra9122@mail.ruПчелинаС. Н.PchelinaS. N.sopchelina@hotmail.ruШляхтоЕ. В.ShlyakhtoE. V.e.shlyakhto@almazovcentre.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion FederationRussian Federation2017300620172424045Copyright © Пейкришвили Н.Э., Дора С.В., Волкова А.Р., Пантелеева А.А., Пчелина С.Н., Шляхто Е.В., 20172017Пейкришвили Н.Э., Дора С.В., Волкова А.Р., Пантелеева А.А., Пчелина С.Н., Шляхто Е.В.Peikrishvili N.E., Dora S.V., Volkova A.R., Panteleeva A.A., Pchelina S.N., Shlyakhto E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/415Введение

Введение. Диффузный токсический зоб (ДТЗ) – аутоиммунное заболевание, в основе которого лежит образование аутоантител к рецептору тиреотропного гормона. За последние десятилетия отмечается неуклонный рост рецидива тиреотоксикоза после окончания консервативной терапии. При этом достоверных критериев, позволяющих прогнозировать эффективность медикаментозной терапии, не существует. В литературе широко обсуждается, что полиморфизм генов интерлейкинов (ИЛ) влияет как на предрасположенность к ДТЗ, так и на особенности его клинического течения.

Целью исследования явилась оценка роли полиморфных вариантов С-572G (rs1800796) гена IL6 и С-1112Т (rs1800925) гена IL13 в развитии и клиническом течении ДТЗ.

Материал и методы

Материал и методы. Молекулярно-генетический анализ полиморфных вариантов гена, кодирующих провоспалительные цитокины, был выполнен у 270 больных ДТЗ и 200 лиц без аутоиммунной патологии. Идентификация С-572G гена IL6 и С-1112Т гена IL13 проведена методом ПЦР с последующим рестрикционным анализом.

Результаты исследования

Результаты исследования. Установлено, что носительство аллеля -572G гена IL6 ассоциируется с повышением риска рецидива тиреотоксикоза и отсутствием ремиссии ДТЗ в 1,3 раза (р=0,031, OR=1,3, 95 % ДИ 0,98–1,76), а носительство генотипа С-1112С гена IL13 – в 2,3 раза (р=0,026, OR=2,3, 95 % ДИ 1,09–4,82). Полученные результаты позволили выявить новые генетические маркеры неблагоприятного течения у больных ДТЗ, жителей Санкт-Петербурга.

Relevance

Relevance. Diffuse toxic goiter (DTG) is an autoimmune thyroid disease, which is based on the excessive secretion of autoantibodies to thyroid-stimulating hormone receptor (TRAb). Over the last decades, high relapse rate of thyrotoxicosis is observed after withdrawal of conservative therapy. At the same time, there are no reliable criteria to predict the efficiency of drug therapy. It is widely discussedin literature that singlenucleotide polymorphism (SNP) at cytokine-encoding genesnot only confers susceptibility to the DTG, but also has impact on the features ofclinical course of the disease .

The aim of this study was to determine whether the SNPs in -572C/G (rs1800796) of IL6 or -1112C/Т (rs1800925) of IL13 genes can influence thedevelopment and clinical course of the diffuse toxic goiter (DTG).

Materials and methods

Materials and methods. We examined 270 patients with diffuse toxic goiter and 200 healthy persons (reference subjects)with the help of molecular genetic analysis of polymorphic variants of the gene encoding the Pro-inflammatory cytokines. Identification of C-572G of IL6 gene and C-1112T of IL13gene was performed using the PCR method followed by the restriction analysis.

Results

Results. We determined that the carriage of -572G allele of the rs1800796 in IL6 gene isassociated with the growth of recurrence risk of thyrotoxicosis and the absence of remission of DTGin 1.3 times (р=0.031, OR=1.3, 95 %, CI 0.98–1.76) and the carriage of CC genotype of the rs1800925 in IL13 – in 2.3 times (р=0.026, OR=2.3, 95 %, CI 1.09–4.82) respectively. The obtained results allowed to revealnew genetic markers of an adverse course in patients with diffuse toxic goiter, Saint Petersburg residents.

диффузный токсический зобС-572G IL6С-1112T IL13ИЛ-6diffuse toxic goiterC-572G of IL6C-1112T of IL13IL-6ПСПбГМУ им. ак. И.П.ПавловаReferencesVitti P., Rago T., Chiovato L. et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment // Thyroid. – 1997. – № 7. – Р. 369–375.Vitti P., Rago T., Chiovato L., et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997; (7):369–375.Benker G., Reinwein D., Kahaly G. et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study // The Eur. Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clinical Endocrinology (Oxf). – 1998. – № 49. – Р. 451–457.Benker G., Reinwein D., Kahaly G., et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clinical Endocrinology (Oxf). 1998; 49:451–457.Hedley A. J., Young R. E., Jones S. J. et al. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Scottish Automated Followup Register Group // Clin. Endocrinology (Oxf). – 1989. – № 31. – Р. 209–218.Hedley A.J., Young R.E., Jones S.J., et al. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Scottish Automated Follow-up Register Group. Clinical Endocrinology (Oxf). 1989;31: 209–218Komiya I., Yamada T., Sato A. et al. Remission and recurrence of hyperthyroid Graves’ disease during and after methimazole treatment when assessed by IgE and interleukin 13 // Journ. of Clin. Endocrinology and Metabolism. – 2001. – № 86. – Р. 3540–3544.Komiya I., Yamada T., Sato A., et al. Remission and recurrence of hyperthyroid Graves’ disease during and after methimazole treatment when assessed by IgE and interleukin 13. Journal of Clinical Endocrinology and Metabolism. 2001; 86:3540-3544Nanba T., Watanabe M., Inoue N., Iwatani Y. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease // Thyroid. – 2009. – № 19 (5). – Р. 495–501.Nanba T., Watanabe M., Inoue N., Iwatani Y. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid 2009, 19(5):495–501.Kocjan T., Wraber B., Repnik U., Hojker S. Changes in Th1/Th2 cytokine balance in Graves’ disease // Pflugers Arch. – 2000. – № 440. – Р. 94–95.Kocjan T., Wraber B., Repnik U., Hojker S. Changes in Th1/Th2 cytokine balance in Graves’ disease. Pflugers Arch. 2000;440: 94-95Li C., Yuan J., Zhu Y. et al. Imbalance of Th17/Treg in Different Subtypes of Autoimmune Thyroid Diseases // Cellular Physiology and Biochemistry. – 2016. – № 40. – Р. 245–252.Li C., Yuan J., Zhu Y., Yang X., et al. Imbalance of Th17/Treg in Different Subtypes of Autoimmune Thyroid Diseases. Cellular Physiology and Biochemistry. 2016;(40):245-252Khan F. A., Al-Jameil N., Khan M. F. et al. Thyroid dysfunction: an autoimmune aspect // Int. Journ. of Clin. and Experiment. Medicine. – 2015. – № 8 (5). – Р. 6677–6681.Khan F.A., Al-Jameil N., Khan M.F., Al-Rashid M., Tabassum H. Thyroid dysfunction: an autoimmune aspect. International Journal of Clinical and Experimental Medicine. 2015;8(5):6677-6681Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls // Danish Med. Journ. – 2016. – № 63 (2).Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Danish Medical Journal. 2016 Feb;63(2)Salvi M., Pedrazzoni M., Girasole G. et al. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking // Eur. Journ. of Endocrinology. – 2000. – № 143. – Р. 197–202.Salvi M., Pedrazzoni M., Girasole G. et al. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology. 2000;(143):Zhu W., Liu N., Zhao Y. et al. Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves’ disease // Journ. of Endocrinologic. Investigation. – 2010. – № 33 (10). – Р. 751–755.97-202Inoue N., Watanabe M., Nakaguchi A., Ueda D. et al. Functional polymorphisms affecting Th1 differentiation are associated with the severity of autoimmune thyroid diseases // Endocrine Journ. – 2017.Zhu W., Liu N., Zhao Y., Jia H., Cui B., Ning G. Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves’ disease. Journal of Endocrinological Investigation. 2010;33(10):751-755.Niyazoglu M., Baykara O., Koc A. et al. Association of PARP-1, NF-κB, NF-κBIA and IL-6, IL-1β and TNF-α with Graves Disease and Graves Ophthalmopathy // Gene. – 2014. – № 547 (2). – Р. 226–232.Inoue N., Watanabe M., Nakaguchi A., Ueda D. et al. Functional polymorphisms affecting Th1 differentiation are associated with the severity of autoimmune thyroid diseases. Endocrine Journal. 2017.Inoue N., Watanabe M., Morita M. et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases // Clinic. and Experiment. Immunology. – 2011. – № 163 (3). – Р. 318–323.Niyazoglu M., Baykara O., Koc A. et al. Association of PARP-1, NF-κB, NF-κBIA and IL-6, IL-1β and TNF-α with Graves Disease and Graves Ophthalmopathy. Gene. 2014; 547(2): 226-232Bednarczuk T., Placha G., Jazdzewski K. et al. Interleukin-13 gene polymorphisms in patients with Graves’ disease // Clinic. Endocrinology (Oxf). – 2003. – № 59 (4). – Р. 519–525.Inoue N., Watanabe M., Morita M., et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clinical and Experimental Immunology. 2011;163(3):318-323.Simmonds M. J., Heward J. M., Franklyn J. A., Gough S. C. IL-13 and chromosome 5q31-q33: problems of identifying association within regions of linkage to Graves’ disease // Clinic. Endocrinology (Oxf). – 2005. – № 63. – Р. 695–697.Bednarczuk T., Placha G., Jazdzewski K. et al. Interleukin-13 gene polymorphisms in patients with Graves’ disease. Clinical Endocrinology (Oxf). 2003;59(4):519-525.Hiromatsu Y., Fukutani T., Ichimura M. et al. Interleukin-13 gene polymorphisms confer the susceptibility of Japanese populations to Graves’ disease // Journ. of Clinic. Endocrinology and Metabolism. – 2005. – № 90 (1). – Р. 296–301.Simmonds M.J., Heward J.M., Franklyn J.A., Gough S.C. IL-13 and chromosome 5q31- q33: problems of identifying association within regions of linkage to Graves’ disease. Clinical Endocrinology (Oxf). 2005; 63:695–697Blin N., Stafford D. W. A general method for isolation of high molecular weight DNA from eukaryotes // Nucleic. Acids Res. – 1976. – № 3 (9). – Р. 2303–2308.Hiromatsu Y., Fukutani T., Ichimura M. et al. Interleukin-13 gene polymorphisms confer the susceptibility of Japanese populations to Graves’ disease. Journal of Clinical Endocrinology and Metabolism. 2005;90(1):296-301.Mikos H., Mikos M., Obara-Moszynska M., Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease // Endokrynologia Polska. – 2014. – № 65 (2). – Р. 150–155.Blin N., Stafford D.W. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3(9):2303-2308McKenzie A. N. Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13 // Pharmacology & Therapeutics. – 2000. – № 88 (2). – Р. 143–151.Mikos H., Mikos M., Obara-Moszynska M., Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease. Endokrynologia Polska. 2014;65(2):150-155McKenzie AN. Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacology & Therapeutics. 2000;88(2):143-151McKenzie AN. Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacology & Therapeutics. 2000;88(2):143-151

The authors declare that there are no conflicts of interest present.